Loading
HKSEHealthcareMedical - Care Facilities
Latest quote
HK$0.73
+HK$0.02 · +2.82%
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Latest quote
HK$0.73
+HK$0.02 · +2.82%
Regular session · HKT · Market data may be delayed.
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Day range
Current HK$0.73
52-week range
Current HK$0.73
Regular session · HKT · Market data may be delayed.
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Day range
Current HK$0.73
52-week range
Current HK$0.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 448.02M CNY | 388.31M CNY | 538.65M CNY | 472.17M CNY | 470.51M CNY |
| Cost of goods sold | 416.9M CNY | 455.55M CNY | 603.74M CNY | 746.53M CNY | 659.81M CNY |
| Gross profit | 31.12M CNY | −67.25M CNY | −65.09M CNY | −197.46M CNY | −92.76M CNY |
| Research and development | 27.44M CNY | 31.18M CNY | 36.44M CNY | 41.32M CNY | 40.38M CNY |
| Selling, general, and administrative | 186.58M CNY | 259.36M CNY | 252.97M CNY | 274M CNY | 102.87M CNY |
| Operating expenses | 263.29M CNY | 330.3M CNY | 288.58M CNY | 358.81M CNY | 376.27M CNY |
| Interest income | 658.5K CNY | 733K CNY | 7.28M CNY | 7.79M CNY | 5.47M CNY |
| Interest expense | 120.33M CNY | 109.27M CNY | 108.01M CNY | 274.48M CNY | 435.31M CNY |
| Depreciation and amortization | 149.13M CNY | 114.06M CNY | 152.01M CNY | 114.29M CNY | 83.79M CNY |
| Operating income | −232.16M CNY | −371.21M CNY | −353.67M CNY | −477.56M CNY | −393.05M CNY |
| Net income | −249.96M CNY | −443.22M CNY | −373.09M CNY | −541.4M CNY | −816.59M CNY |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
